Suppressor of the endogenous interferon-gamma
AssigneeTigo GmbH
InventorsIvan Ivanov, Genoveva Nacheva, Stefan Petrov, Hans-Guenther Grigoleit
Life of this patent
Estimating the term…
Abstract
The invention relates to suppressors of endogenous human interferon-gamma (INF-γ) applicable in treatment of diseases associated with impaired activity of endogenous IFN-γ. The suppressors of the invention are useful in treating autoimmune diseases and for prevention of graft arteriosclerosis and rejection of organs in allograft transplanted patients. The invention includes inactive analogues or variants of IFN-γ having preserved affinity to the IFN-γ receptor, genetically modified in the domain responsible for triggering the signal transduction pathway.
Claims16
An IFN-γ modulator composition comprising an IFN-γ suppressor, wherein the IFN-γ suppressor has preserved affinity to an IFN-γ receptor, wherein the IFN-γ suppressor is a variant of SEQ ID NO:
- 5, and wherein the amino acid sequence of the IFN-γ suppressor comprises at least one modification selected from the group consisting of amino acid substitutions at positions 86, 87, 88, and combinations thereof.
Dependencies are inferred from the claim text.